Welcome to our dedicated page for SAB BIOTHERAPEUTICS SEC filings (Ticker: SABS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SAB Biotherapeutics, Inc. (SAB BIO) SEC filings page for ticker SABS provides access to the company’s official regulatory disclosures as a clinical-stage biopharmaceutical issuer on Nasdaq. These documents are a primary source for detailed information on SAB BIO’s governance, equity structure, and other material corporate events related to its development of fully human immunoglobulin G (hIgG) and human anti-thymocyte immunoglobulin (hATG) therapies, including its lead program SAB-142 for autoimmune type 1 diabetes.
In SAB BIO’s Form 8-K filings, investors can find reports on matters such as Board of Directors changes and stockholder approvals. For example, one 8-K describes the resignation of two directors and a reduction in the size of the Board, noting that the departures were not due to disagreements over company operations, policies, or practices. Another 8-K details the results of a special meeting of stockholders, where stockholders approved amendments to the 2021 Omnibus Equity Incentive Plan, including increases in the maximum number of shares available under the plan and adjustments to the plan’s evergreen share increase, as well as approval of a proposal related to potential issuance of common stock upon conversion of Series B Convertible Preferred Stock under Nasdaq rules.
On Stock Titan, these and other SAB BIO filings are updated from the SEC’s EDGAR system and can be reviewed alongside AI-powered summaries. AI analysis helps explain complex items such as equity plan amendments, preferred stock conversion terms, and governance changes in clear language, saving time when reading lengthy forms. Users can quickly identify key sections of 8-Ks, 10-Ks, and 10-Qs, and can also monitor how equity incentives and capital structure decisions may relate to the company’s ongoing clinical development of SAB-142 and its broader human IgG platform.
For those researching SABS, this page centralizes SAB Biotherapeutics’ historical and current SEC reports, with tools to interpret the implications of each filing without manually parsing every line of legal and accounting text.
RA Capital and affiliated persons report owning 4,401,500 shares of SAB Biotherapeutics common stock, representing 9.99% of the outstanding shares following an automatic conversion tied to a private placement.
The position arose from the Fund's purchase of 171,400 Series B Preferred Shares on July 22, 2025 at $175 per share (aggregate $29,995,000). Upon stockholder approval at a special meeting, 44,015 Preferred Shares converted into 4,401,500 common shares. The Preferred Stock includes a Beneficial Ownership Blocker preventing conversion above 9.99% (adjustable up to 19.99% with 61 days' notice).
Commodore Capital LP and related filers report beneficial ownership of 4,522,977 shares of SAB Biotherapeutics, Inc. common stock, representing 9.9% of the outstanding class based on 45,108,294 shares reported by the issuer. The position includes 4,401,500 shares issued to Commodore Capital Master LP upon conversion of Series B Convertible Preferred Stock after stockholder approval on September 26, 2025, plus 121,477 additional shares issuable upon conversion but subject to a 9.99% ownership limitation (the "Ownership Blocker"). The filing discloses that larger pools of shares issuable on conversion and under warrants are excluded from the reported aggregate because they are constrained by the Ownership Blocker. Voting and dispositive power over the reported shares is shared among the filers; no filer reports sole voting or dispositive power.
SAB Biotherapeutics insider conversion increases public float via Sessa Capital. The filing reports that Series B Convertible Preferred Stock held by Sessa Capital (Master), L.P. automatically converted into 1,740,000 common shares at an effective conversion price of $1.75 per underlying share, reflecting conversion of 17,400 preferred shares. After the conversion the Sessa Parties are reported to beneficially own 2,198,457 common shares in aggregate, held indirectly through related entities.
The Preferred Stock was purchased by the Fund for an aggregate price of $39,987,500 under a July 21, 2025 purchase agreement. The filing discloses a 4.99% beneficial ownership cap that limits further conversions that would push the Sessa Parties above that threshold. Andrew Moin is identified as a board director of the issuer and is an Analyst and Partner with the Fund; the reported holdings are described as indirect and subject to the stated ownership limitation.
Sessa Capital reported the automatic conversion of Series B Convertible Preferred Stock into common stock of SAB Biotherapeutics (SABS) on 09/29/2025. The filing shows the Fund received 1,740,000 common shares as a result of converting 17,400 preferred shares at an effective price of $1.75 per share. The Fund originally acquired the preferred shares for an aggregate purchase price of $39,987,500 under a July 21, 2025 purchase agreement. After the conversion, the reporting persons collectively beneficially owned 2,198,457 shares of common stock. The conversion is subject to a 4.99% beneficial ownership limitation that restricts further conversions that would exceed that threshold.
SAB Biotherapeutics, Inc. reported that on September 30, 2025, Christine Hamilton and Jeffrey Spragens resigned from its Board of Directors. Their departures were made in line with a letter agreement between the company and RA Capital Healthcare Fund, L.P. related to a July 2025 private placement of securities. Following these resignations, the Board size was reduced from 11 to nine members. The company stated that the resignations were not due to any disagreement regarding its operations, policies, or practices and expressed appreciation for both directors’ service.
SAB Biotherapeutics, Inc. stockholders approved two major equity-related proposals at a special meeting. First, they approved the potential issuance of more than 19.99% of the company’s outstanding common stock upon conversion of its Series B Convertible Preferred Stock at less than the Nasdaq “minimum price,” a step that may be deemed a change of control under Nasdaq rules.
Second, stockholders approved an amendment to the 2021 Omnibus Equity Incentive Plan that increases the share pool for awards by 24,180,000 shares to an aggregate of 31,932,466 shares and raises the maximum annual “evergreen” increase from 10,000,000 shares to 73,750,000 shares. The Plan amendment passed with 5,089,862 votes for and 951,598 against, while the Series B conversion proposal passed with 5,502,026 votes for and 515,275 against.
SAB Biotherapeutics describes clinical and corporate disclosures in this amended shelf filing. The filing reports that SAB-142 showed a favorable safety profile in Phase 1 across a dose range of 0.03 mg/kg to 2.5 mg/kg, with 0% reported serum sickness and 0% reported anti-drug antibodies, supporting chronic ambulatory dosing. The company states SAB-142 demonstrated sustained immunomodulation and a multi-target mechanism of action analogous to rabbit ATG on parameters correlative to C-peptide preservation.
The prospectus reiterates extensive risk-factor topics and lists permitted methods for secondary distributions by selling stockholders. It also references recent SEC filings, including the 2024 annual report and quarterly and current reports filed in 2025, without providing financial results in the included excerpt.
Alexandra Kropotova, Chief Medical Officer of SAB Biotherapeutics, Inc. (ticker: SABSW), reported a routine insider transaction dated 09/19/2025. The Form 4 shows 1,977 shares of common stock were disposed through withholding to satisfy tax obligations on vested restricted stock units (RSUs). Following the transaction, she beneficially owns 45,272 shares, which include 29,340 vested shares and 15,932 RSUs that remain subject to vesting.
The filing is a standard Section 16 disclosure reflecting tax-withholding on RSU vesting rather than an open-market sale or purchase. The form was signed by Ms. Kropotova on 09/22/2025 and does not disclose any derivative transactions or other changes in ownership form.